The AJMC® Asthma compendium is a comprehensive resource for clinical news and expert insights for the chronic lung disease.
July 3rd 2025
Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
June 25th 2025
Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.
October 3rd 2024
The legacy of redlining continues to harm minority health, with Black individuals facing higher rates of health issues, linked to environmental factors and limited access to resources in regions previously redlined.
August 1st 2024
Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies.
July 8th 2024
Researchers link vaccination and reduced asthma symptoms; providers warn against overburdening and security risks; insurers’ practices lead to questionable diagnoses
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage
Reflecting on the Real-World Use of Biologic Therapy in Asthma Management
Advancing Cystic Fibrosis Management: The Evolving Role of Specialty and Managed Care Pharmacists
Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.